PRA International's Drug Safety Experts to Speak at Safety Congress

Key Topic: Global Compliance Challenges

RALEIGH, North Carolina, September 13, 2010 - PRA International, a leading Clinical Research Organization, announces
that two of its leading drug safety experts will present at the 4th annual
World Drug Safety Congress to be held in London 14 -17 September 2010. PRA
will also host a conference exhibit.

Dr. Sabine Richter, PRA's Vice President of Safety & Risk Management
(SRM) and a conference chair, will make the opening remarks for the Thursday
morning session on pre-clinical and clinical safety strategies. Dr. Angelika
Schneider, Director of PRA's Drug Safety Centers in Europe, Asia-Pacific and
Africa, will discuss the challenges of global compliance in the current
regulatory environment in her Thursday afternoon session. She will also
review a PRA-developed repository that contains the diverse safety reporting
requirements for more than 60 countries.

At booth 11, PRA drug safety managers will be available to discuss PRA's
successful experience in SRM engagements for sponsor.

As vice president, Dr. Richter is responsible for all aspects of PRA's
SRM services. To ensure consistent high performance and regulatory
compliance, Dr. Richter has developed robust procedures and quality control
measures. Dr. Schneider has nearly 15 years of experience in clinical
research and pharmacovigilance. Over the last six years, she has led several
large pharmacovigilance projects both in the pre- and post-marketing
settings.

PRA provides safety and risk management services during the entire
product life cycle. Our SRM team of more than 110 experts is available to our
clients for consultancy as well as routine and specialty pharmacovigilance
services. Our drug safety centers are based in Mannheim, Germany;
Charlottesville, VA (US); and Sao Paulo, Brazil.

For more information about the World Drug Safety Congress, navigate to
www.praintl.com and click on "Events."

About PRA International

PRA International conducts clinical trials in more than 85 countries
across 6 continents and provides services through all phases of clinical
development. PRA performs studies in all therapeutic areas, with
specialization in Oncology, Neurosciences, Respiratory/Allergy,
Cardiovascular and Infectious Diseases. In the last five years, PRA has
supported over 2,700 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience,
combined with extensive local knowledge and our differentiating PERSONAL
ELEMENT enable our project teams to deliver consistent and on time
performance for our clients. This unique PRA philosophy - THE PERSONAL
ELEMENT - recognizes that true client service comes only from trained,
empowered and dedicated employees who are encouraged to use innovation and
their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit
www.PRAinternational.com, email Endpoints@PRAintl.com or call our
Global Headquarters at +1-919-786-8200.

Roger Boutin, Director of Marketing of PRA International, Inc., +1-434-951-3924